|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current evidence for histone deacetylase inhibitors in pancreatic cancer显示文摘Pancreatic cancer is one of the most aggressive human cancers,with more than 200 000 deaths worldwide every year.Despite recent efforts,conventional treatment approaches,such as surgery and classic chemotherapy,have only slightly improved patient outcomes.More effective and well-tolerated therapies are required to reverse the current poor prognosis of this type of neoplasm.Among new agents,histone deacetylase inhibitors (HDACIs) are now being tested.HDACIs have multiple biological effects related to acetylation of histones and many non-histone proteins that are involved in regulation of gene expression,apoptosis,cell cycle progression and angiogenesis.HDACIs induce cell cycle arrest and can activate the extrinsic and intrinsic pathways of apoptosis in different cancer cell lines.In the present review,the main mechanisms by which HDACIs act in pancreatic cancer cells in vitro,as well as their antiproliferative effects in animal models are presented.HDACIs constitute a promising treatment for pancreatic cancer with encouraging anti-tumor ef-fects,at well-tolerated doses. | Ioannis Koutsounas Constantinos Giaginis Efstratios Patsouris Stamatios Theocharis | 2013 | World Journal of Gastroenterology2013，19，6： | 9 |
| 2 | Histone deacetylase inhibitors and pancreatic cancer:Are there any promising clinical trials?显示文摘Pancreatic cancer,although not very frequent,has an exceptionally high mortality rate,making it one of the most common causes of cancer mortality in developed countries.Pancreatic cancer is difficult to diagnose,allowing few patients to have the necessary treatment at a relatively early stage.Despite a marginal benefit in survival,the overall response of pancreatic cancer to current systemic therapy continues to be poor,and new therapies are desperately needed.Histone deacetylase(HDAC) enzymes play an important role in the development and progression of cancer and HDAC inhibitors(HDACIs) have been shown to induce differentiation and cell cycle arrest,activate the extrinsic or intrinsic pathways of apoptosis,and inhibit invasion,migration and angiogenesis in different cancer cell lines.As a result of promising preclinical data,various HDACIs are being tested as either monotherapeutic agents or in combination regimens for both solid and hematological malignancies.Vorinostat was the first HDACI approved by the Food and Drug Administration for patients with cutaneous T-cell lymphoma.The use of HDACIs in clinical trials,in pretreated and relapsed patients suffering from advanced pancreatic cancer is discussed.Unfortunately,clinical data for HDACIs in patients with pancreatic cancer are inadequate,because only a few studies have included patients suffering from this type of neoplasm and the number of pancreatic cancer patients that entered HDACIs phase Ⅱ/Ⅲ trials,among others with advanced solid tumors,is very limited.More studies recruiting patients with pancreatic cancer remain to determine the efficiency of these therapies. | Ioannis Koutsounas Constantinos Giaginis Stamatios Theocharis | 2013 | World Journal of Gastroenterology2013，19，8： | 3 |
| 3 | Heat Shock Pro-tein-27,-60 and-90 expressinon in gastric cancer:association withclinicopathological variables and patient survival显示文摘 | Giaginis C Daskalopulou SS Vgenopoulou S | 2009 | BMC Gastroen-terol2009，9，： | 1 |
| 4 | MCM-2 and MCM-5expression in gastric adenocarcinoma : clinical significance andcomparison with Ki-67 proliferative marker显示文摘 | GiaginisC Giagini A Tsourouflis G | 2011 | Digestive disea-ses and sciences2011，56，3： | 1 |
| 5 | Biomechanical response of ascending thoracic aortic aneurysms: association with structural remodeling 显示文摘 | Sokolis DP Kritharis EP Giagini AT | 2012 | Comput Methods Biomech Biomed Engin2012，15，3： | 1 |
| 6 | Correlation of Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) and Retinoid X Receptor-alpha (RXR-alpha) expression with clinical risk factors in patients with advanced carotid atherosclerosis 显示文摘 | Giaginis C Klonaris C Katsargyris A | 2011 | Med Sci Monit2011，17，： | 1 |
| 7 | Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clin- icopathological parameters and tumor proliferative capacity 显示文摘 | Giaginis C Georgiadou M Dimakopoulou K | 2009 | Dig Dis Sci2009，54，2： | 1 |
| 8 | Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism显示文摘 | Giaginis C Tsantili-Kakoulidou A Theocharis S | 2007 | Fund Clin Pharmacol2007，21，3： | 1 |
| 9 | Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival 显示文摘 | Theocharis S Giaginis C Parasi A | 2007 | Dig Dis Sci2007，52，9： | 1 |
| 10 | Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival 显示文摘 | Giaginis C TsoukaJas N Bournakis E | 2014 | BMC Clin Pathol2014，14，1： | 1 |
| 11 | Clinical significance of MCM2 and MCM5 expression in colon cancer:association with clinicopathological parameters and tumor proliferative capacity 显示文摘 | Giaginis C Georgiadou M Dimakopouloa K | 2009 | Dig Dis Sci2009，54，2： | 1 |
| 12 | Correlation of Peroxi- some Proliferator-Activated Receptor-gamma ( PPAR-gamma ) and Retinoid X Receptor-alpha(RXR-alpha) expression with clinical risk factors in patients with advanced carotid atherosclerosis 显示文摘 | Giaginis C Klonaris C Katsargyris A | 2011 | Med Sci Monit2011，17，7： | 1 |
| 13 | Ephrin(Eph)receptor A1,A4,A5 and A7 expression in human non-small cell lung carcinoma:associations with clinicopathological parameters,tumor proliferative capacity and patients'survival显示文摘 | Giaginis C Tsoukalas N Bournakis E | 2014 | BMC Clin Pathol2014，14，1： | 1 |
| 14 | Clinical Significance of MCM-2 and MCM-5 Expression in Colon Cancer: Association with Clinicopathological Parameters and Tumor Proliferative Capacity 显示文摘 | Giaginis C Georgiadou M Dimakopoulou K | 2009 | Dig Dis Sci2009，54，2： | 1 |
| 15 | NF-κB signaling at the cross- roads of inflammation and atherogenesis : searching for new therapeutic links 显示文摘 | Pateras I Giaginis C Tsigris C | 2014 | Expert Opin Ther Targets2014，18，10： | 1 |
| 16 | Coxsackie virus and adenovirus receptor expression in human endometrial adenocarcinoma: possible clinical implications 显示文摘 | Giaginis CT Zarros AC Papaefihymiou MA | 2008 | World J Surg Oncol2008，6，： | 1 |
| 17 | DNA repair systems as targets of cadmium toxicity显示文摘 | Giaginis C Gatzidou E Theocharis S | 2006 | Toxicol Appl Pharmacol2006，213，3： | 1 |
| 18 | Peroxisome proliferatoractivated recepto>gamma ligands as investigational modulators of angiogenesis 显示文摘 | Giaginis C Margeli A Theocharis S | 2007 | Expert Opin Investig Drugs2007，16，10： | 1 |
| 19 | NF - KB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links显示文摘 | Pateras I Giaginis C Tsigris C | 2014 | Expert Opin Ther Targets2014，18，9： | 1 |
| 20 | Pregnane X Receptor (PXR) at the Crossroads of Human Metabolism and Disease显示文摘 | Ioannis Koutsounas Stamatios Theocharis Efstratios Patsouris Constantinos Giaginis | 2013 | Current Drug Metabolism2013，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员